Long-term trastuzumab (Herceptin®) treatment in a continuation study of patients with HER2-positive breast cancer or HER2-positive gastric cancer

by Müller, Volkmar, Clemens, Michael, Jassem, Jacek, Al-Sakaff, Nedal, Auclair, Petra, Nüesch, Eveline, Holloway, Debbie, Shing, Mona, Bang, Yung-Jue
Published in BMC Cancer (2018)

Subcutaneous vs Intravenous Trastuzumab for Patients With ERBB2-Positive Early Breast Cancer: Final Analysis of the HannaH Phase 3 Randomized Clinical Trial

by Jackisch, Christian, Stroyakovskiy, Daniil, Pivot, Xavier, Ahn, Jin Seok, Melichar, Bohuslav, Chen, Shin-Cheh, Meyenberg, Christoph, Al-Sakaff, Nedal, Heinzmann, Dominik, Hegg, Roberto
Published in JAMA Oncol (2019)

Adjuvant Subcutaneous Trastuzumab for HER2‐Positive Early Breast Cancer: Subgroup Analyses of Safety and Active Medical Conditions by Body Weight in the SafeHer Phase III Study

by Jung, Kyung Hae, Ataseven, Beyhan, Verrill, Mark, Pivot, Xavier, De Laurentiis, Michelino, Al‐Sakaff, Nedal, Lauer, Sabine, Shing, Mona, Gligorov, Joseph, Azim, Hamdy A.
Published in Oncologist (2018)

Quality of Life in the Trastuzumab for Gastric Cancer Trial

by Satoh, Taroh, Bang, Yung-Jue, Gotovkin, Evgeny A., Hamamoto, Yasuo, Kang, Yoon-Koo, Moiseyenko, Vladimir M., Ohtsu, Atsushi, Van Cutsem, Eric, Al-Sakaff, Nedal, Urspruch, Alexa, Hill, Julie, Weber, Harald A., Chung, Hyun-Cheol
Published 2014

11 years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial

by Cameron, David, Piccart-Gebhart, Martine J, Gelber, Richard D, Procter, Marion, Goldhirsch, Aron, de Azambuja, Evandro, Castro, Gilberto, Untch, Michael, Smith, Ian, Gianni, Luca, Baselga, Jose, Al-Sakaff, Nedal, Lauer, Sabine, McFadden, Eleanor, Leyland-Jones, Brian, Bell, Richard, Dowsett, Mitch, Jackisch, Christian
Published in Lancet (2017)